Profile
Efficacy
Praluent® is associated with a reduction in major adverse cardiovascular events in the ODYSSEY OUTCOMES CVOT2
Flexibility of dose
Praluent® offers different dosing options to suit your patient1
Safety Profile
Praluent® offers a favourable long-term safety and tolerability profile demonstrated over 5 years in ODYSSEY OUTCOMES1,2
1. Praluent Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/8093/smpc. Accessed March 2023
2. Schwartz G, et al. N Engl J Med 2018;379:2097–2107.
Indication, Mechanism of Action and Administration
.png/jcr:content/Dyslip.png)
.png)
Expert Hub Videos
Resources include links to videos from Dr Derek Connolly (Consultant Cardiologist, Birmingham UK) discussing topics such as recommended guidance, current clinical trials and peer-2-peer sharing of clinical practice.
Lipid Optimization in ACS patients
In the following video Dr Connolly discusses the evidence for LDL-C causality, the difference between high risk and very high risk patients and the reasons why a post-ACS patient should be screened for lipid optimisation.
The Intensive Lipid-Lowering Approach
In the following video Dr Connolly explains the intensive lipid-lowering therapy approach in high and very high risk ASCVD patients and why this is needed.
Implementing the Intensive Lipid-Lowering Approach
In the following video Dr Connolly discusses implementing the intensive lipid-lowering therapy approach in clinical practice.
Get in touch with the Dyslipidaemia Team
MAT-XU-2201545 (v3.0)
Date of Preparation: February 2023
MAT-XU-2204604 (v2.0)
Date of Preparation: March 2023
